Showing 3074 results for "hemophilia A"

Filter By

A single infusion of the experimental gene therapy GS001 safely increased the levels of factor VIII (FVIII) — the missing clotting protein in hemophilia A  — for almost three years, effectively reducing bleeds and the need for replacement therapies at doses much lower than those used in currently approved…

An experimental therapy may help remove harmful antibodies that reduce the effectiveness of factor replacement therapies in hemophilia A, potentially offering a new way to overcome one of the most significant complications of standard care. The therapy uses chimeric autoantibody receptor T cells, or CAAR-T cells. These are…

In boys and men with severe hemophilia A, starting prophylaxis — preventive treatment given regularly to reduce bleeding — early and maintaining regular physical activity were each linked to a lower risk of hemophilic arthropathy, a progressive form of joint damage caused by repeated bleeding, according to a real-world…

A young woman who sought emergency care for severe pain and swelling of her left hand five weeks after giving birth was ultimately diagnosed with acquired hemophilia A — caught early enough that she did not require surgery. That’s according to a new report detailing the woman’s case, which,…

Testing levels of thrombin — an enzyme that helps blood clot — in people with acquired hemophilia A could help doctors fine-tune care for these patients when both clot-promoting and blood-thinning medications are used. That’s the conclusion drawn by researchers in the Netherlands, who found that thrombin testing in…

Pfizer said the U.S. Food and Drug Administration (FDA) will review the company’s request to expand approval of its preventive treatment Hympavzi (marstacimab) to cover all people with hemophilia A or B ages 6 and older. Hympavzi is FDA-approved to treat hemophilia A and B in patients ages…

Altuviiio (efanesoctocog alfa) reduced bleeding and was safe for boys and young men with severe hemophilia A, according to a recent study. Researchers also reported an increase in participants’ confidence in everyday activities and no return of neutralizing antibodies that may inhibit treatment, even in patients who are usually…

People with hemophilia A and their caregivers, as well as healthcare providers, have shown a strong interest in a new blood-testing device being developed to make blood clotting tests faster and easier to access, according to a recent study. The device, called EnzySystem, allows for measuring the activity of…